Dr. Erkan has received speaking fees and/or honoraria for his service on the Genentech Advisory Board and the Human Genome Sciences/GlaxoSmithKline Speakers Bureau (less than $10,000 each) and has received a research grant from Genentech.
A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome†
Version of Record online: 28 JAN 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 65, Issue 2, pages 464–471, February 2013
How to Cite
Erkan, D., Vega, J., Ramón, G., Kozora, E. and Lockshin, M. D. (2013), A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis & Rheumatism, 65: 464–471. doi: 10.1002/art.37759
ClinicalTrials.gov identifier: NCT00537290.
- Issue online: 28 JAN 2013
- Version of Record online: 28 JAN 2013
- Accepted manuscript online: 2 NOV 2012 12:17PM EST
- Manuscript Accepted: 11 OCT 2012
- Manuscript Received: 9 MAY 2012
Additional Supporting Information may be found in the online version of this article.
|ART_37759_sm_SupplInfo1.doc||60K||Supplementary Data 1|
|ART_37759_sm_SupplInfo2.doc||74K||Supplementary Data 2|
|ART_37759_sm_SupplInfo3.doc||55K||Supplementary Data 3|
|ART_37759_sm_SupplInfo4.doc||132K||Supplementary Data 4|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.